1. Kim V, Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am. 2001. 19:839–859.
2. The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol. 1990. 43:703–709.
3. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008. 358:1037–1052.
4. Maron BA, Loscalzo J. Homocysteine. Clin Lab Med. 2006. 26:591–609. vi.
5. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999. 19:217–246.
6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995. 10:111–113.
7. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998. 158:585–593.
8. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996. 334:759–762.
9. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007. 44:62–69.
10. Oh SE, Jung JH, Yoon SB, Yoon HY, Park JK, Lee DH, et al. A case of pulmonary thromboembolism in a patient with hyperhomocysteinemia. Tuberc Respir Dis. 2007. 62:211–216.
11. Weiss N, Keller C, Hoffmann U, Loscalzo . Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med. 2002. 7:227–239.
12. Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007. 146:761–767.
13. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004. 291:565–575.